Cross-Platform Validation of axoCells™ hiPSC-Derived Cardiomyocytes as a Better Human Model for Preclinical Cardiotoxicity Studies

The poster Cross-Platform Validation of axoCells™ hiPSC-Derived Cardiomyocytes as a Better Human Model for Preclinical Cardiotoxicity Studies presents Axol Bioscience’s ventricular cardiomyocytes tested across three platforms to assess electrophysiology, contractility, and pharmacology.

Key highlights include:

• Platforms Used:
  • MEA (Axion Maestro Pro): Field potential duration (FPD), spike amplitude, QT interval
  • FLEXcyte 96: Contractile force, beat rate, beat duration
  • CellOPTIQ: Voltage-sensitive dye recordings, APD90, TRise
• Marker Validation:
  • ICC confirms expression of TNNT2, ACTN2, MYH7, ACTC1
  • RNAseq shows 4x higher KCNH2 (hERG) expression than human heart reference
• Pharmacological Profiling:
  • Dofetilide: FPD prolongation and arrhythmias
  • Nifedipine: FPD shortening
  • Lidocaine: Amplitude reduction
  • Ranolazine & Azimilide: APD modulation and early afterdepolarizations
• Chamber-Specific Insights:
  • S-Bay K8644 increases beat duration via calcium release
  • Carbachol and 4-AP show minimal effect on ventricular cells, confirming atrial specificity
• CiPA Compound Testing:
  • Graded responses to 28 compounds aligned with known proarrhythmic risk

This model supports predictive cardiac safety screening and drug development with high physiological relevance.

Featured Axol Products:

• axoCells™ Ventricular Cardiomyocytes – ax2508
• axoCells™ Cardiomyocyte Maintenance Media – ax2530